{"brief_title": "Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease", "brief_summary": "Trial evaluating the improvement in survival at 180 days of two therapies (Atgam versus ABX-CBL, a monoclonal antibody) in patients with acute graft versus host disease that does not respond to steroid therapy.", "condition": "Graft Vs Host Disease", "intervention_type": "Drug", "intervention_name": "ABX-CBL", "criteria": "Inclusion Criteria: - Recipient of single allogeneic stem cell transplant from any donor type - Time post transplant less than 100 days - Received no treatment for GVHD other than steroids Exclusion Criteria: - Recipient of second allogeneic stem cell transplant or subsequent lymphocyte product from the donor post transplant - IBMTR index less than A - Received any murine product in the past - Diagnosed with chronic GVHD - Received Atgam later than day 10 post transplant - Change to prophylactic regimen for acute GVHD within 72 hours of randomization", "gender": "All", "minimum_age": "1 Year", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00035880.xml"}